Physically Active During Cancer Treatment (FAKT)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

66 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-27

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized controlled trial aims to investigate whether an individually tailored exercise program and nutritional guide can affect the development of self-reported peripheral sensory neuropathy and fatigue in patients with colorectal cancer receiving adjuvant chemotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Physical Activity and Functioning in Palliative Cancer Patients - a Clinical Randomised Trial

NCT00397774

Cancer

COMPLETED PHASE3

Physical Training and Cancer-a Multicenter Clinical Trial

NCT02473003

Breast Cancer Colorectal Cancer Prostate Cancer

ACTIVE_NOT_RECRUITING NA

REACT - Resistance Exercise After Cancer Treatment

NCT07159815

Cancer

RECRUITING NA

Physical Activity and Its Impact on Colon Cancer Surgery

NCT03947840

Colon Cancer Physical Activity

COMPLETED

Cancer, Physical Activity and Quality of Life- a Longterm Follow up

NCT04083300

Cancer Rehabilitation Stress Disorder +3 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Colorectal cancer is the second most common cancer in Norway with 4332 new cases in 2017. Standard of care is radical surgery followed by adjuvant chemotherapy for some, depending on the stage of the disease. Most commonly, a combination of Oxaliplatin and Capecitabine or 5-fluorouracil is given for 3 to 6 months.

A common side effect of Oxaliplatin is peripheral sensory neuropathy, which occur in different degree in over 90 % of the patients. There is no established treatment to prevent or reduce Oxaliplatin induced peripheral neuropathy. A few minor studies have been published indicating that physical activity can reduce the patient's experience of chemotherapy-induced peripheral neuropathy.

Most patients receiving chemotherapy will experience fatigue in some degree. It has been shown in several studies that exercise can reduce cancer related fatigue, though most studies have been performed among women with breast cancer.

There are a limited number of randomized controlled clinical trials looking at the effects of physical exercise during ongoing adjuvant chemotherapy in colorectal cancer patients. Thus, there is a clear need for further studies on physical exercise in this patient group.

In the period from January 2017 to November 2018 the investigators did a non-randomized pilot study to test the feasibility of the exercise intervention in this patient group, and to calculate sample size for the randomized trial.

The 9-item European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Chemotherapy Induced Peripheral Neuropathy (CIPN20) sensory subscale will be used to measure peripheral sensory neuropathy. Each item is rated on a scale from 1 ("not at all") to 4 ("very much"), and the total raw score ranges from 9 to 36. The raw scores will be linearly transformed to a 0 to 100 scale (higher scores represent worse CIPN severity). A difference of 10 is considered clinically significant. The sample size calculation is based on a two-sided t-test. Aim is to demonstrate a difference in patient-reported sensory peripheral neuropathy between the two groups 3 months after randomization. It is postulated that the intervention group develops less degree of peripheral sensory neuropathy than the control group. Based on the answers obtained from the questionnaire in the pilot study, a standard deviation (SD) of 12.5 is assumed for the change between baseline and 3 months. To detect a difference of 10 with a strength of 80% and with a significance level of 0.05, there should be 25 patients in each arm. A drop out of 20% is taken into account based on experience in the pilot study. This suggests that 64 patients should be included in this study.

Patients scheduled for adjuvant Oxaliplatin based combination chemotherapy will be recruited from cancer clinics in Norway, and randomized to an intervention group or a control group. Before randomization and start of the first cycle of chemotherapy, the study participants will perform baseline testing and fill in the different questionnaires.

The intervention with exercise training starts around the same time as adjuvant chemotherapy starts, usually 4 -6 weeks postoperatively, and lasts as long as the adjuvant treatment, i.e. 3 - 6 months. Participants start with an individual session with a physiotherapist at the hospital. A treadmill submaximal heart rate test is done to give the participants instructions regarding the recommended intensity zones during cardio training.

The exercise intervention consists of three components: sensorimotor training (SMT), strength exercises, and aerobic training. The SMT and strength exercises are carried out twice a week as guided training together with the physiotherapist, each session lasting 30 minutes. In addition, instruction is given to do minimum 90 minutes a week of moderate intensity (60 - 75 % of maximum heart rate) home-based aerobic training, or 45 minutes with high intensity (80 - 85 % of maximum heart rate) aerobic training.

Participants in the intervention group receive a pulse watch to guide the intensity of the aerobic exercise. The participants will register completed training in a training log. Based on previous experience with physical activity and exercise, individual guidance is provided.

Once a month participants will fill out the form, Patient-Generated Subjective Global Assessment Short Form (PG-SGA SF), and will be referred to a nutritionist if the score is 2 or higher. Regardless of the score on this form and group affiliation, participants may be referred to a nutritionist based on clinical judgment.

In the pilot study, also a qualitative study was carried out with semi-structured interviews evaluating patient's expectations and experiences regarding the physical exercise training. Depending on the information power obtained in the current sample, additional interviews of patients in this randomized trial might be done.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms, Colorectal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Exercise training and nutritional guide

Standard recommendations regarding physical activity and nutrition. An individually tailored exercise program and nutritional guide during adjuvant chemotherapy.

Group Type EXPERIMENTAL

Exercise training and nutritional guide

Intervention Type BEHAVIORAL

30 minutes of a combination of sensorimotor- and strength training guided by a physical therapist twice a week. In addition 90 minutes a week of moderate intensity aerobic training or 45 minutes a week of high intensity aerobic training. Once a month the participants will fill out the form, PG-SGA SF, and he or she will be referred to a nutritionist if the score is 2 or higher. The intervention period lasts as long as the participants receives adjuvant chemotherapy, i.e. 3 - 6 months.

Standard follow-up care

Intervention Type OTHER

standard recommendations regarding physical activity and nutrition during the period with adjuvant chemotherapy.

Standard follow-up care

Standard recommendations regarding physical activity and nutrition.

Group Type ACTIVE_COMPARATOR

Standard follow-up care

Intervention Type OTHER

standard recommendations regarding physical activity and nutrition during the period with adjuvant chemotherapy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Exercise training and nutritional guide

30 minutes of a combination of sensorimotor- and strength training guided by a physical therapist twice a week. In addition 90 minutes a week of moderate intensity aerobic training or 45 minutes a week of high intensity aerobic training. Once a month the participants will fill out the form, PG-SGA SF, and he or she will be referred to a nutritionist if the score is 2 or higher. The intervention period lasts as long as the participants receives adjuvant chemotherapy, i.e. 3 - 6 months.

Intervention Type BEHAVIORAL

Standard follow-up care

standard recommendations regarding physical activity and nutrition during the period with adjuvant chemotherapy.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Radical resection for colon- or rectal cancer past 3 months, and scheduled for adjuvant, Oxaliplatin-based, combination chemotherapy.
* Histologically confirmed adenocarcinoma.
* Able to read and understand Norwegian.
* Able to carry out the intervention.
* Performance Status (PS) 0 - 2.

Exclusion Criteria

* Serious comorbidities that contraindicate physical exercise, based on the treating physician's assessment.
* Unable to give informed consent.
* Treated for other cancer last 5 years prior to inclusion (with the exceptions of basal cell carcinoma of the skin and carcinoma in situ in the cervix).
* Prior treatment with Oxaliplatin

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No